Navigation Links
Testosterone EIA Reproductive Markers 020-DR-1559

ProductsTestosterone EIA Reproductive Markers 020-DR-1559
Company ALPCO Diagnostics
Item Testosterone EIA Reproductive Markers 020-DR-1559
Features 
Description Testosterone is the most important androgen secreted into the blood. In males, testosterone is secreted primarily by the Leydig cells of the testes; in females ca. 50% of circulating testosterone is derived from peripheral conversion of androstenedione, ca. 25% from the ovary and ca. 25% from the adrenal glands. The Testosterone ELISA KIT is based on the competition principle and the microplate separation. An unknown amount of Testosterone present in the sample and a fixed amount of Testosterone conjugated with horseradish peroxidase compete for the binding sites of a monoclonal Testosterone antiserum coated onto the wells. After one hour incubation the microtiterplate is washed to stop the competition reaction. Having added the substrate solution the concentration of Testosterone is inversely proportional to the optical density measured.
Info ALPCO DiagnosticsCall ALPCO Diagnostics to buy products (US and Canada only; other locations use number below) USACanada1-866-466-7731

Customer Service: (800) 592-5726
Web site: http://www.alpco.com

Related medicine products :

1. Free Testosterone EIA Test
2. Ultra-Sensitive Testosterone EIA
3. Testosterone EIA Test
4. Testosterone EIA
5. Testosterone EIA kit
6. Testosterone ELISA
7. Testosterone Enzyme Immunoassay Test Kit
8. Testosterone RIA Test
9. Free Testosterone RIA Test
10. Testosterone, Adult Male
11. Testosterone, Bioavailable & Sex Hormone Binding Globulin (Includes Total Testosterone), Adult Male
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6JumpStart Invests in Checkpoint Surgical 6118 1JumpStart Invests in Checkpoint Surgical 6118 2JumpStart Invests in Checkpoint Surgical 6118 3Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2